WHEATON® Announces Acquisition of CELLineTM
News Jul 10, 2012
WHEATON has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corporation. WHEATON has also entered into a long term strategic partnership with Wilson Wolf Manufacturing Corporation for further product development in high density cell culture devices for the production of concentrated, cell secreted products. CELLine Flasks are known by their loyal users to be easy to implement and are trusted worldwide for small scale suspension and adherent cultures. The CELLine dual membrane bioreactor system is designed as a humane alternative to hybridoma culture in the peritoneal cavity of mice, also known as the ascites method.
The flasks enhance small scale bio-production for antibody and protein generation. Conventional in vivo or in vitro cell culture methods can be laborious, result in low cell density, and require significant purification. The CELLine Flasks address these three areas of limitation in a single use, repeatable technology. CELLine Flasks are ready-to-use and disposable, produce high cell density and high product concentration, while significantly reducing culture and processing time. “We are excited to bring this innovative, high growth technology to WHEATON and to our customers around the world, enabling our customers’ life’s work. These products, combined with the existing WHEATON portfolio, support the advancement of antibody and protein research, development and production,” says Stephen R. Drozdow, President of WHEATON. “We are also proud to have an ongoing partner with Wilson Wolf, for collaboration and further advancement of cell culture products,” he added.
Watching Stem Cells Repair Spinal Cord in Real TimeNews
Clues to the reversal of brain and spine injury.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE